Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Javelin Pharmaceuticals is to receive a $750,000 grant from the US National Institutes of Health and the National Cancer Institute to advance clinical development for PMI-150, an intranasal formulation of ketamine being developed by the company for pain control.
Subscribe to our email newsletter
The grant, awarded through the small business innovation research (SBIR) program, will support phase II safety and efficacy studies of PMI-150 in a multicenter, randomized, double blind, and placebo-controlled clinical trial in patients suffering from episodic acute moderate-to-severe pain.
The company used an earlier SBIR grant to conduct a 20-patient phase I pilot study of the drug that established proof of principle for intranasal administration of ketamine for the treatment of episodic breakthrough pain in patients taking opioid analgesics for chronic pain.
“Javelin is honored by our success in this highly competitive grant process from such a prestigious source,” said Dr Daniel Carr, the company’s CEO and chief medical officer.